Jordan Zwick is an experienced leader in corporate strategy and business development in the biopharmaceutical sector.

Mr. Zwick served as strategic advisor to Prometheus Biosciences prior to its sale to Merck in June 2023. He was also a member of the board of directors and audit committee at Theratechnologies, Inc., where he played a substantial role in the sale of the company to Future Pak in 2025.

Previously, Mr. Zwick held the role of SVP, Corporate Business Development and Investor Relations at Amarin Corp, where he closed multiple transactions for global partnering of the lead asset. He later became SVP, Chief Strategy Officer at InflaRx N.V., leading corporate strategy, business and corporate development, investor relations and contributing materially to the company’s public financings.

Mr. Zwick brings extensive industry operating experience from companies including Medtronic, Salix Pharmaceuticals and Bausch Health. As part of the team that sold Salix to Valeant Pharmaceuticals (now Bausch Health Companies) for $14.5 billion in 2015, he ultimately became head of strategy at the Salix business unit, overseeing business development, alliance management, strategic planning and portfolio management, and playing a key role in the turnaround story of Bausch Health.

He holds a B.A. and M.S. from Florida Atlantic University and an M.B.A from the University of San Francisco. He serves on the board of TruTechnologies, owned by LLR Partners, and is on the Advisory Board of the McKenna Life Sciences, Business and Entrepreneurship (MLSBE) Program at Arizona State University.